Drug Topics

OCTOBER 4, 2024

Check out important updates from the FDA for the week of September 30.

FDA 201

FDA 201

STAT

OCTOBER 4, 2024

Experimental vaccines and therapeutics to combat the deadly Marburg virus will begin arriving this weekend in Rwanda, where they will be used in clinical trials expected to begin soon, a U.S. government official confirmed on Friday. There are currently no licensed vaccines or drugs to prevent or treat Marburg, a cousin of the Ebola family of viruses that transmits and causes illness in the same way as Ebola.

Vaccines 145

Vaccines 145

Drug Topics

OCTOBER 4, 2024

Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.

200

200

Pharmacy Times

OCTOBER 4, 2024

The new screening test provides an easier, convenient option for patients seeking to screen themselves for colorectal cancer.

FDA 145

FDA 145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

STAT

OCTOBER 4, 2024

Sam Altman, co-founder of OpenAI and co-creator of ChatGPT,  keeps saying artificial intelligence will help cure cancer. Altman’s going further these days, envisioning a future where an AI essentially replaces the principal investigator. In a discussion last month that was widely circulated this week on social media, Altman recounted chatting with a cancer researcher about a time when an AI would issue experimental plans and tasks to human scientists to complete.

139

139

Pharmacy Times

OCTOBER 4, 2024

The treatment aims to reduce prolonged QTc interval in patients with long QT syndrome.

FDA 138

FDA 138

Pharmacy Times

OCTOBER 4, 2024

Research showed that children born via assisted reproductive technology were 36% more likely to develop heart defects.

132

132

STAT

OCTOBER 4, 2024

Next year’s Medicare Advantage market will be two things at once: remarkably stable broadly, but rife with changes under the surface. Health insurance companies will still offer older adults a lot of plan choices with low, or completely free, premiums. That’s why the federal government expects enrollment in the $500 billion Medicare Advantage program to grow once again in 2025 — a stark contrast from insurers’ cries that modest payment reforms would damage them and se

Insurance 137

Insurance Health Insurance Companies 137

Pharmacy Times

OCTOBER 4, 2024

Nivolumab is the only PD-1 inhibitor to show statistically significant and clinically meaningful benefits in non-small cell lung cancer compared with chemotherapy.

Chemotherapy 132

Chemotherapy FDA 132

STAT

OCTOBER 4, 2024

As primary care physicians, we see a scene play out almost daily. A patient is sitting in front of us, explaining her symptoms: She could have difficulty breathing, stress at home, fatigue. We know there is nothing more important than being fully present. However, our minds and eyes keep darting to the computer screen and the growing inbox of messages from other patients: “I forgot my Lipitor for a week, should I double up tomorrow?

Vaccines 129

Vaccines 129

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

OCTOBER 4, 2024

Significant polarization surrounding COVID-19 vaccinations in late 2020 and early 2021 looked to have had an impact in increasing vaccine hesitancy.

Vaccines 132

Vaccines 132

Fierce Pharma

OCTOBER 4, 2024

After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.

Hospitals 128

Hospitals 128

Pharmacy Times

OCTOBER 4, 2024

High cholesterol levels are known risk factors for atherosclerotic cardiovascular disease.

131

131

STAT

OCTOBER 4, 2024

Exact Sciences won Food and Drug Administration approval on Friday for an improved version of a stool-based screening test for colon cancer that should result in fewer cancer-free patients receiving unnecessary follow-up colonoscopies. The FDA approved the test, Cologuard Plus, for adults 45 and up with an average risk of cancer based on results from a large clinical trial, dubbed Blue-C, which recruited more than 20,000 participants.

FDA 126

FDA 126

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

PharmaVoice

OCTOBER 4, 2024

Cassava Sciences’ beleaguered investigational Alzheimer’s therapy is in two phase 3 studies.

124

124

Pharmacy Times

OCTOBER 4, 2024

Major biomarkers for cognitive impairment were observed in hospitalized patients with neurological symptoms.

Hospitals 123

Hospitals 123

STAT

OCTOBER 4, 2024

Georgina Peacock vividly remembers a night when she admitted 20 babies, all struggling to breathe, into the hospital where she was doing her pediatric medical training. The illness that was robbing them of breath? Respiratory syncytial virus, or RSV. Peacock and many others who are responsible for the care of the country’s youngest children have been moving heaven and earth for the past year and a bit, to make experiences like that a thing of the past.

Hospitals 117

Hospitals 117

Pharmacy Times

OCTOBER 4, 2024

Carrie Koenigsfeld, PharmD, FAPhA, discusses an overview of RSV, including its transmission, incidence, seasonality, and clinical presentation.

122

122

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Drug Topics

OCTOBER 4, 2024

Cologuard Plus is approved for adults aged 45 years and older who are at average risk for the disease.

FDA 112

FDA 112

NF2 BioSolutions

OCTOBER 4, 2024

Hello everyone, For the last 3 years, I have been a NF2 BioSolutions-funded PhD student working within Manchester alongside Grace Gregory, and it has been such a rewarding and positive experience, not only for my personal development, but for driving forward our understanding of NF2 -related Schwannomatosis ( NF2 SWN) and potential new treatments. Alas, my PhD has finally come to an end, but I’m please to share with you some of the key findings from my work that will hopefully change the ways in

Immunization 111

Immunization Communication Hospitals 111

Drug Topics

OCTOBER 4, 2024

Researchers aimed to determine whether or not opioids were appropriate for treating adolescents experiencing chronic pain.

112

112

pharmaphorum

OCTOBER 4, 2024

Bristol Myers Squibb (BMS) has been granted approval by the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).

FDA 111

FDA 111

Fierce Pharma

OCTOBER 4, 2024

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating $825 million upfront—plus another $250 million in potential commercial milestones—to get its hands on the global rights to Sanofi’s rare disease biologic Enjaymo. In 2022, Enjaymo became the first and only therapy specifically approved by the FDA for treating patients with the uncommon blood disorder cold agglutinin disease.

FDA 110

FDA 110

pharmaphorum

OCTOBER 4, 2024

FDA declares an end to tirzepatide shortage, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

FDA 110

FDA 110

Fierce Healthcare

OCTOBER 4, 2024

Though their margins have largely remained level, hospitals are starting to get a handle on length of stay and per-patient expense growth as demand for inpatient care remains strong, according to A | Kaufman Hall's monthly index report showed continued demand and more efficient inpatient care, but muted revenue gains. A concurrent report on third quarter M&A also outlined a spike in dealmaking.

Hospitals 109

Hospitals 109

NF2 BioSolutions

OCTOBER 4, 2024

Hi everyone! What a journey it has been over the last 3 years, being one of the first two NF2 BioSolutions UK and Europe PhD students alongside Adam! I have enjoyed every moment, and I have made the most of all the opportunities to pass my way through the University of Manchester, NF2 research community and the Charity, all of whom have driven this research forward.

Immunization 105

Immunization Communication 105

Fierce Healthcare

OCTOBER 4, 2024

A proposed rule from the Centers for Medicare & Medicaid Services (CMS) released Oct. | CMS is looking to shake up the risk adjustment model and wants the ability to suspend shady brokers from the insurance marketplace, the agency wrote among other updates in a new proposed rule.

Insurance 106

Insurance 106

The Checkup by Singlecare

OCTOBER 4, 2024

You open the medicine cabinet to take a dose of fluconazole prescribed to tackle a stubborn yeast infection. Later, as you meet friends for dinner, you wonder whether it’s safe to enjoy a glass of wine. Fluconazole , also sold under the brand name Diflucan , is a commonly used antifungal medication, but generally, it’s not recommended to drink while taking it.

Immunization 105

Immunization FDA 105

Pharmacy Times

OCTOBER 4, 2024

When considering the 3-stage framework, perhaps a greater emphasis on pre-treatment phase research could help identify some of the more individual traits used to better predict patient outcomes.

101

101

The Checkup by Singlecare

OCTOBER 4, 2024

Many people struggle with managing blood sugar levels and dealing with excess weight. If you’re in this situation, you might feel frustrated and worried about developing Type 2 diabetes. This double burden isn’t just exhausting; it may also be harmful to your health. A healthcare provider might suggest a medication like Wegovy (semaglutide) to manage these problems.

Dosage 98

Dosage Insurance Insurance Coverage FDA 98

European Pharmaceutical Review

OCTOBER 4, 2024

A study has reported an approach for optimising metronidazole colonic delivery systems, to increase their potential efficacy when treating diverticulitis. Researchers developed intestinal colon-coated sustained-release matrix metronidazole tablets, using a Quality by Design (QbD) approach. Arévalo-Pérez et al. noted that metronidazole is a synthetic nitroimidazole and has activity against anaerobic bacteria.

Dosage 98

Dosage 98

Pharmaceutical Technology

OCTOBER 4, 2024

Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue…

98

98

The Honest Apothecary

OCTOBER 4, 2024

Founded in 1947 with a mission to provide compassionate care while pursuing cutting-edge research to combat cancer, Dana-Farber Cancer Institute, is a world leader in cancer treatment and research. One of its most notable fundraising events is the Jimmy Fund Walk, which began in 1989.

97

97